文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

玛伐凯泰治疗非梗阻性肥厚型心肌病:ODYSSEY-HCM试验超声心动图探索性分析

Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-08-27

ODYSSEY-HCM试验虽未达主要终点,本探索性分析显示玛伐凯泰治疗症状性非梗阻性肥厚型心肌病患者48周后,最大左室壁厚度、左室质量指数及E/e'显著降低,但21.5%患者出现LVEF<50%且停药后恢复。

要点

  • 玛伐凯泰可轻度逆转左室肥厚并改善舒张功能,但需警惕LVEF下降。
  • 约1/5患者出现LVEF<50%,中断治疗后恢复。
  • 左房功能参数在48周时显著改善,无房颤者左房容积减小。

核心结论

  • 玛伐凯泰治疗症状性nHCM患者48周可定向改善左室舒张功能及左房功能标志物,轻度逆转左室肥厚相关参数,但约1/5患者出现LVEF<50%且停药后恢复。

研究设计与样本

  • ODYSSEY-HCM为3期随机安慰剂对照试验的探索性分析,纳入580例症状性nHCM患者,随机接受安慰剂或玛伐凯泰(5 mg/d,根据LVEF在1–15 mg间滴定),评估基线至48周超声心动图变化。

主要发现

  • 48周时玛伐凯泰组最大左室壁厚度安慰剂校正差异为-2.1 mm(95%CI:-2.5至-1.7 mm),左室质量指数为-3.8 g/m2(95%CI:-7.1至-0.5 g/m2),E/e'为-1.3(95%CI:-2.0至-0.7)。
  • 玛伐凯泰组LVEF降低-5.3%(95%CI:-5.9%至-4.1%;P<0.01),LVEF<50%者62例(21.5%),安慰剂组5例(1.7%),停药后均恢复。
  • 维持LVEF≥50%的玛伐凯泰组患者(n=212)48周时LV整体纵向应变改善-0.4%(95%CI:-0.8%至-0.05%;P<0.05)。
  • 左房收缩应变改善-1.1%(95%CI:-1.8%至-0.4%),管道应变改善-1.4%(95%CI:-0.6%至-2.3%)(P<0.05);无房颤者左房容积指数降低-2.6 mL/m2(95%CI:-4.7至-1.11 mL/m2;P=0.009)。

临床怎么用

  • 玛伐凯泰用于症状性nHCM时需密切监测LVEF,警惕LVEF<50%的发生,出现后应中断治疗并复查。
  • 超声心动图参数(LVEF、左室壁厚度、E/e'、左房应变)可用于评估治疗反应与安全性。

局限性

  • 本分析为探索性分析,主要终点未达预期,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status). OBJECTIVES: This exploratory analysis of the phase 3, randomized, placebo-controlled trial evaluated echocardiographic changes in nHCM patients from baseline to week 48. METHODS: Symptomatic nHCM patients were randomized to placebo or mavacamten (5 mg/d, titrated between 1 and 15 mg based on left ventricular ejection fraction [LVEF]). Echocardiographic assessments of LV systolic/diastolic function and left atrial (LA) function were performed at baseline and week 48. RESULTS: Among 580 randomized patients (mean age 56 ± 15 years, 45.9% women), baseline measures included LVEF (65.8 ± 4%), maximal LV wall thickness (20.8 ± 4 mm), LV mass index (122.3 ± 31 g/m2), average E/e' (13.3 ± 6), and LV-global longitudinal strain (-13.2 ± 4%). LA parameters included volume index (43.5 ± 16 mL/m2), reservoir strain (19.1 ± 9%), and conduit strain (-11.6 ± 6%). At week 48, there was significant placebo-corrected treatment difference with patients on mavacamten demonstrating significant reduction in maximal LV wall thickness (-2.1 mm [95% CI: -2.5 to -1.7 mm]), LV mass index (-3.8 g/m2 [95% CI: -7.1 to -0.5 g/m2]), and E/e' (-1.3 [95% CI: -2.0 to -0.7]), with a -5.3% [95% CI: -5.9% to -4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF <50% occurred in 62 patients (21.5%) in the mavacamten arm vs 5 (1.7%) in the placebo arm and recovered following drug interruption. Patients in the mavacamten group maintaining LVEF ≥50% throughout the study (n = 212) demonstrated an improvement in LV-global longitudinal strain at week 48 (-0.4% [95% CI: -0.8% to -0.05%]; P < 0.05). LA functional parameters including contractile (-1.1% [95% CI: -1.8% to -0.4%]) and conduit (-1.4% [95% CI: -0.6% to -2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas LA volume was significantly reduced in patients without atrial fibrillation (-2.6 mL/m2 [95% CI: -4.7 to -1.11 mL/m2]; P = 0.009). CONCLUSIONS: Symptomatic nHCM patients treated with mavacamten demonstrated directional improvements in markers of LV diastolic and LA function, modest regression in LV hypertrophy-related parameters, but 1 in 5 demonstrated an LVEF <50%, which reversed following therapy interruption.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai MY, Okushi Y, Jadam S, et al. Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial. J Am Coll Cardiol. 2025. PMID: 40864019. doi:10.1016/j.jacc.2025.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。